Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Immix Biopharma, Inc. (NASDAQ:IMMX) has earned a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $20.6667.

A number of research firms have recently issued reports on IMMX. Mizuho boosted their target price on Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a report on Monday, March 30th. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Bank of America started coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating and a $27.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Tuesday, April 21st. Finally, Morgan Stanley initiated coverage on shares of Immix Biopharma in a research note on Wednesday, March 25th. They set an “overweight” rating and a $20.00 target price for the company.

Immix Biopharma Trading Up 0.2%

Shares of Immix Biopharma stock traded up $0.02 on Friday, hitting $11.11. 1,624,045 shares of the company traded hands, compared to its average volume of 2,266,294. The stock’s 50 day moving average price is $9.41 and its 200-day moving average price is $8.25. The company has a market cap of $604.50 million, a PE ratio of -12.08 and a beta of 0.09. Immix Biopharma has a 52 week low of $1.94 and a 52 week high of $12.14.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. As a group, research analysts anticipate that Immix Biopharma will post -0.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Immix Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the business. Eventide Asset Management LLC purchased a new position in Immix Biopharma during the fourth quarter valued at approximately $13,331,000. Blue Owl Capital Holdings LP acquired a new position in shares of Immix Biopharma in the fourth quarter valued at approximately $5,158,000. Concurrent Investment Advisors LLC acquired a new position in shares of Immix Biopharma during the 4th quarter worth $143,000. Jump Financial LLC acquired a new stake in shares of Immix Biopharma in the 4th quarter worth about $177,000. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Immix Biopharma in the 4th quarter valued at $176,000. 11.26% of the stock is owned by institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.